Stansberry Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Stansberry Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-71,133	Closed	-$9.18M	–	57
2019 Q4	$9.18M	Buy	71,133 +20,235	+40%	+$2.04M	3.74%	8
2019 Q3	$3.83M	Buy	50,898 +1,495	+3%	+$177K	1.69%	17
2019 Q2	$7.51M	Sell	49,403 -1,332	-3%	-$162K	2.96%	9
2019 Q1	$6.05M	Sell	50,735 -75	-0.1%	-$9.64K	2.07%	16
2018 Q4	$5.54M	Sell	50,810 -2,413	-5%	-$302K	1.74%	11
2018 Q3	$8.6M	Sell	53,223 -4,186	-7%	-$572K	2.41%	13
2018 Q2	$7.59M	Sell	57,409 -26,782	-32%	-$2.53M	2.51%	11
2018 Q1	$6.24M	Sell	84,191 -1,856	-2%	-$124K	3.06%	7
2017 Q4	$4.79M	Buy	+86,047	New	+$4.56M	2.06%	17

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Stansberry Asset Management's SRPT Position: Q1 2020 in Review

Stansberry Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2020, closing a stake of 71,133 shares — an estimated $9.18M sold.

Stansberry Asset Management first reported a position in SRPT in Q4 2017 and held it in 9 quarters. The position peaked at $9.18M in Q4 2019. 365 funds tracked by Wall St. Rank hold SRPT as of Q1 2020.

Stansberry Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2020 after selling out during the quarter.
Stansberry Asset Management sold 71,133 Sarepta Therapeutics shares in Q1 2020, an estimated $9.18M.
Stansberry Asset Management first reported a position in Sarepta Therapeutics in Q4 2017 and held it in 9 quarters.
Stansberry Asset Management's Sarepta Therapeutics position peaked at $9.18M in Q4 2019.
365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2020.

Based on Stansberry Asset Management's 13F filing for Q1 2020, filed 15 May 2020.